A cceptance of new technology depends on early clinical trials of safety and efficacy followed by the requisite "midterm" and finally "long-term" follow-up. We prefer to rely on the results of randomized trials for understanding how new technology might fit into patient care strategy. But trials are flawed by recruitment and may be slow to enroll, which makes for a long wait for initial results and thus follow-up. In addition, pa-
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that the presence of CAD and other comorbidities in TAVR patients affects them long term, but whether "TAVR-induced" factors such as PVL and pacemaker need contribute to long-term outcomes needs further study.
